221 related articles for article (PubMed ID: 31724191)
21. Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03.
Taverna C; Martinelli G; Hitz F; Mingrone W; Pabst T; Cevreska L; Del Giglio A; Vanazzi A; Laszlo D; Raats J; Rauch D; Vorobiof DA; Lohri A; Biaggi Rudolf C; Rondeau S; Rusterholz C; Heijnen IA; Zucca E; Ghielmini M
J Clin Oncol; 2016 Feb; 34(5):495-500. PubMed ID: 26712227
[TBL] [Abstract][Full Text] [Related]
22. Comparative assessment of pharmacokinetics, and pharmacodynamics between RTXM83™, a rituximab biosimilar, and rituximab in diffuse large B-cell lymphoma patients: a population PK model approach.
Candelaria M; Gonzalez D; Fernández Gómez FJ; Paravisini A; Del Campo García A; Pérez L; Miguel-Lillo B; Millán S
Cancer Chemother Pharmacol; 2018 Mar; 81(3):515-527. PubMed ID: 29362903
[TBL] [Abstract][Full Text] [Related]
23. Intralesional Rituximab Injection for Low-Grade Conjunctival Lymphoma Management.
Demirci H; Ozgonul C; Diniz Grisolia AB; Elner VM
Ophthalmology; 2020 Sep; 127(9):1270-1273. PubMed ID: 32336490
[No Abstract] [Full Text] [Related]
24. Long-term data on the proposed adalimumab biosimilar BCD-057 in patients with moderate to severe psoriasis: A randomized controlled trial.
Samtsov AV; Bakulev AL; Khairutdinov VR; Kokhan MM; Korotaeva TV; Minullin IK; Vylegzhanina OA; Dubenskiy VV; Khalilov BV; Khotko AA; Zykova OS; Chumachenko IV; Lukyanov AM; Artemeva AV; Pukhtinskaia PP
PLoS One; 2022; 17(2):e0263214. PubMed ID: 35130291
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial.
Davies A; Merli F; Mihaljević B; Mercadal S; Siritanaratkul N; Solal-Céligny P; Boehnke A; Berge C; Genevray M; Zharkov A; Dixon M; Brewster M; Barrett M; MacDonald D
Lancet Haematol; 2017 Jun; 4(6):e272-e282. PubMed ID: 28476440
[TBL] [Abstract][Full Text] [Related]
26. Efficacy, Safety and Pharmacokinetics of Up to Two Courses of the Rituximab Biosimilar CT-P10 Versus Innovator Rituximab in Patients with Rheumatoid Arthritis: Results up to Week 72 of a Phase I Randomized Controlled Trial.
Yoo DH; Suh CH; Shim SC; Jeka S; Molina FFC; Hrycaj P; Wiland P; Lee EY; Medina-Rodriguez FG; Shesternya P; Radominski S; Stanislav M; Kovalenko V; Sheen DH; Myasoutova L; Lim MJ; Choe JY; Lee SJ; Lee SY; Kim SH; Park W
BioDrugs; 2017 Aug; 31(4):357-367. PubMed ID: 28612179
[TBL] [Abstract][Full Text] [Related]
27. Rituximab biosimilars for B-cell lymphomas: a decade of real-world experience from India.
Nair R; Radhakrishnan VS; Mallath MK
Lancet Haematol; 2021 Aug; 8(8):e548-e549. PubMed ID: 34329574
[No Abstract] [Full Text] [Related]
28. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
Smith SM; Pitcher BN; Jung SH; Bartlett NL; Wagner-Johnston N; Park SI; Richards KL; Cashen AF; Jaslowski A; Smith SE; Cheson BD; Hsi E; Leonard JP
Lancet Haematol; 2017 Apr; 4(4):e176-e182. PubMed ID: 28314699
[TBL] [Abstract][Full Text] [Related]
29. Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial.
Park W; Božić-Majstorović L; Milakovic D; Berrocal Kasay A; El-Khouri EC; Irazoque-Palazuelos F; Molina FFC; Shesternya P; Miranda P; Medina-Rodriguez FG; Wiland P; Jeka S; Chavez-Corrales J; Garmish O; Linde T; Rekalov D; Hrycaj P; Krause A; Fomina N; Piura O; Abello-Banfi M; Suh CH; Shim SC; Lee SJ; Lee SY; Kim SH; Yoo DH
MAbs; 2018; 10(6):934-943. PubMed ID: 30010481
[TBL] [Abstract][Full Text] [Related]
30. GP2013: A Rituximab Biosimilar.
Blair HA
BioDrugs; 2017 Oct; 31(5):465-468. PubMed ID: 28921160
[TBL] [Abstract][Full Text] [Related]
31. [Efficacy of rituximab-containing regimens on indolent B-cell lymphoma--a report of 34 cases].
Xia ZJ; Wang FH; Huang HQ; Luo HY; Li YH; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):490-4. PubMed ID: 16613687
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study.
Davies A; Merli F; Mihaljevic B; Siritanaratkul N; Solal-Céligny P; Barrett M; Berge C; Bittner B; Boehnke A; McIntyre C; Macdonald D
Lancet Oncol; 2014 Mar; 15(3):343-52. PubMed ID: 24521993
[TBL] [Abstract][Full Text] [Related]
33. Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial.
Romera A; Peredpaya S; Shparyk Y; Bondarenko I; Mendonça Bariani G; Abdalla KC; Roca E; Franke F; Melo Cruz F; Ramesh A; Ostwal V; Shah P; Rahuman SA; Paravisini A; Huerga C; Del Campo García A; Millán S
Lancet Gastroenterol Hepatol; 2018 Dec; 3(12):845-855. PubMed ID: 30262136
[TBL] [Abstract][Full Text] [Related]
34. Is there a role for a maintenance rituximab in indolent lymphoproliferative diseases other than follicular lymphoma?
Moccia AA; Zucca E; Ghielmini M
Leuk Lymphoma; 2017 Jan; 58(1):30-36. PubMed ID: 27813427
[TBL] [Abstract][Full Text] [Related]
35. A phase I pharmacokinetics trial comparing PF-05280586 (a potential biosimilar) and rituximab in patients with active rheumatoid arthritis.
Cohen S; Emery P; Greenwald M; Yin D; Becker JC; Melia LA; Li R; Gumbiner B; Thomas D; Spencer-Green G; Meng X
Br J Clin Pharmacol; 2016 Jul; 82(1):129-38. PubMed ID: 26909489
[TBL] [Abstract][Full Text] [Related]
36. Accelerated R-COP: a pilot study for the treatment of advanced low grade lymphomas that has a high complete response rate.
Levitt MJ; Gharibo M; Strair R; Schaar D; Rubin A; Bertino JR
J Chemother; 2009 Aug; 21(4):434-8. PubMed ID: 19622463
[TBL] [Abstract][Full Text] [Related]
37. A phase III study of BCD-055 compared with innovator infliximab in patients with active rheumatoid arthritis: 54-week results from the LIRA study.
Lila AM; Mazurov VI; Denisov LN; Nesmeyanova OB; Ilivanova EP; Eremeeva AV; Usacheva JV; Dokukina EA; Chernyaeva EV; Ivanov RA
Rheumatol Int; 2019 Sep; 39(9):1537-1546. PubMed ID: 31292709
[TBL] [Abstract][Full Text] [Related]
38. Rituximab biosimilar for the treatment of diffuse large B-cell lymphoma: a phase 3 randomized study in India.
Patel A; Bhatt N; Prakash SS; Biswas G; Nagarkar R; Roy B; Samal P; Agrawal N; Meshram S; Kaushal A; Satheesh CT; Wategaonkar R; Thiagarajan KV; Jain K; Vijayaveeran P; Mukherjee K; Singh K; Patil T; Jain A; Dolai TK; Jain M; Hingmire S; Gupta TC; Lakshmaiah KC; Rajamanickam D; Nemade B; Goyal V; Mahato P; Mendiratta SK; Doshi M
Cancer Chemother Pharmacol; 2023 Jun; 91(6):457-468. PubMed ID: 37093266
[TBL] [Abstract][Full Text] [Related]
39. Oncological outcome and recurrence pattern analysis after involved-field irradiation in combination with rituximab for early-stage nodal and extranodal follicular lymphoma.
König L; Herfarth K; Hörner-Rieber J; Dietrich S; Wiegel T; Debus J; Viardot A
Strahlenther Onkol; 2020 Aug; 196(8):705-714. PubMed ID: 32377821
[TBL] [Abstract][Full Text] [Related]
40. A Developer's Perspective on Clinical Evidence and Benefits for Rituximab Biosimilar Uptake, with a Focus on CT-P10.
Choi D; Lee S; Kim S; Yoon S
Clin Drug Investig; 2022 Apr; 42(4):285-300. PubMed ID: 35325438
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
